Header Logo

Connection

Carl Maki to Cyclin-Dependent Kinase Inhibitor p21

This is a "connection" page, showing publications Carl Maki has written about Cyclin-Dependent Kinase Inhibitor p21.
  1. p53 and p21(Waf1) are recruited to distinct PML-containing nuclear foci in irradiated and Nutlin-3a-treated U2OS cells. J Cell Biochem. 2010 Dec 01; 111(5):1280-90.
    View in: PubMed
    Score: 0.370
  2. Persistent p21 expression after Nutlin-3a removal is associated with senescence-like arrest in 4N cells. J Biol Chem. 2010 Jul 23; 285(30):23105-14.
    View in: PubMed
    Score: 0.356
  3. Geldanamycin promotes premature mitotic entry and micronucleation in irradiated p53/p21 deficient colon carcinoma cells. Oncogene. 2008 Sep 18; 27(42):5567-77.
    View in: PubMed
    Score: 0.311
  4. Two 4N cell-cycle arrests contribute to cisplatin-resistance. PLoS One. 2013; 8(4):e59848.
    View in: PubMed
    Score: 0.109
  5. Nutlin-3a induces cytoskeletal rearrangement and inhibits the migration and invasion capacity of p53 wild-type cancer cells. Mol Cancer Ther. 2010 Apr; 9(4):895-905.
    View in: PubMed
    Score: 0.088
  6. Transient nutlin-3a treatment promotes endoreduplication and the generation of therapy-resistant tetraploid cells. Cancer Res. 2008 Oct 15; 68(20):8260-8.
    View in: PubMed
    Score: 0.080
  7. Cdk2-dependent Inhibition of p21 stability via a C-terminal cyclin-binding motif. J Biol Chem. 2005 Aug 12; 280(32):29282-8.
    View in: PubMed
    Score: 0.063
  8. Ubiquitination of p53 and p21 is differentially affected by ionizing and UV radiation. Mol Cell Biol. 1997 Jan; 17(1):355-63.
    View in: PubMed
    Score: 0.035
  9. In vivo ubiquitination and proteasome-mediated degradation of p53(1). Cancer Res. 1996 Jun 01; 56(11):2649-54.
    View in: PubMed
    Score: 0.034
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.